Table 4—

Association of matrix metalloproteinase(MMP) single nucleotide polymorphisms and the response after the second cycle of chemotherapy for small cell lung cancer patients

PolymorphismGenotypesStage IIB+IIIAStage IIIB+IVStage IIIBStage IV
Patients nResponsePatients nResponsePatients nResponsePatients nResponse
MMP1
 G-1607GGG/G61 (ref)281 (ref)121 (ref)161 (ref)
G/GG+180.40 (0.05–3.27)781.1 (0.4–3.1)291.3 (0.2–7.6)491.0 (0.3–4.0)
GG/GG
MMP2
 C-735TCC191 (ref)771 (ref)271 (ref)501 (ref)
CT+TT512.8 (1.4–67.4)#272.1 (0.8–5.5)132.6 (0.5–12.5)142.0 (0.5–7.0)
MMP3
 6A-1171 5A6A 6A21 (ref)301 (ref)91 (ref)211 (ref)
6A 5A+5A 5A22N/A761.0 (0.4–2.6)32N/A440.5 (0.2–1.7)
MMP7
 C-153TCC201 (ref)841 (ref)351 (ref)491 (ref)
CT+TT45.7 (0.6–57.2)211.5 (0.5–4.3)60.8 (0.1–8.0)151.7 (0.5–6.1)
 A-181GAA31 (ref)161 (ref)61 (ref)101 (ref)
AG+GG210.5 (0.0–6.6)900.9 (0.3–3.0)351.25 (0.1–12.5)550.7 (0.2–3.2)
MMP9
 C-1562TCC201 (ref)821 (ref)351 (ref)471 (ref)
CT+TT45.7 (0.5–66.7)241.6 (0.5–4.3)60.8 (0.0–6.1)181.9 (0.5–6.1)
MMP12
 A-82GAA201 (ref)681 (ref)291 (ref)391 (ref)
AG+GG32.0 (0.1–28.0)380.5 (0.2–1. 5)120.8 (0.1–4.5)260.4 (0.1–1.5)
 A1082GAA211 (ref)941 (ref)371 (ref)571 (ref)
AG+GG2<0.1 (<0.0–999)120.7 (0.0–2.7)4<0.1 (<0.0–999)81.0 (0.2–5.7)
  • Data are presented as crude OR (95% CI), unless otherwise stated. N/A: not applicable. Bold indicates significance. #: p = 0.03.